A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease
Alireza Faridar, Abdulmunaim M. Eid, Aaron D. Thome, Weihua Zhao, David R. Beers, Maria B. Pascual, Mohammad Obadah Nakawah, Gustavo C. Román, Charles S. Davis, Michael Grundman, Joseph C. Masdeu, Stanley H. Appel
Abstract
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic. CLINICALTRIALS: gov/ct2/show/NCT05821153.
Topics & Concepts
NeurologyMedicineOpen labelImmunotherapyDiseaseClinical trialInternal medicineOncologyPilot trialOpen label studyAdverse effectRandomized controlled trialPsychiatryCancerTryptophan and brain disordersNeuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments